Good morning, everyone. This is John Heerdink. I'm the founding member of the Tribe Public, and also, as many of you know, the managing member of Vista Partners, a registered investment advisor in San Francisco. I wanted to thank you all for coming in from around the world. We're representing close to 30 countries now that are members of the Tribe and growing. Thank you from some new members out of Saudi Arabia, some members out of England that came in here, Netherlands, and of course, all across North America. Thank you for all you Americans for jumping in here today. We're looking forward to meeting with the management team of Atossa Therapeutics, trades on the Nasdaq, symbol ATOS. We have both the CEO and CFO of Atossa Therapeutics today. Once we all allow them to introduce themselves. First, I wanna point out that there are two websites that I have to point you to, for disclaimers. As I'm an investor in the company, and advisor, we have, at Vista Partners, please visit www.vistapglobal.com, Vista Partners. And then at Tribe Public, T-R-I-B-E public.com, P-U-B-L-I-C-K-- C, I'm sorry, dot com. A reminder that, this presentation came about because of you, the Tribe members, wanted to speak with management of Atossa, and you expressed your interest through the wish list and have registered today. I appreciate your participation and look forward to having, both you and the management team of Atossa Therapeutics come back as we progress. I would invite Kyle Guse, the CFO and General Counsel of Atossa, to begin. Thank you so much, Kyle Guse. Great. Thank you very much, John. It's a pleasure to be back here. Again, I'm Kyle Guse. I'm the CFO and General Counsel of Atossa Therapeutics. I've been with the company about 10 years. Before that, I spent most of my career doing biotech, M&A, and capital markets work in Silicon Valley as a lawyer. I hold an MBA, a CPA, and a JD degree in law. Dr. Quay is also on with us. Steve is the founder of the company. He has a PhD and MD. He did his residency at Mass General, which I think is Harvard's largest teaching hospital. He did post-doc work in the MIT in the lab of a Nobel Prize winner. Steve started about half a dozen companies. He has about 6 products that he has invented and taken through FDA approval, probably most famously gadodiamide, which is a contrast agent which has been used, I think, over 70 million times and is currently owned and marketed by GE HealthCare. You know, before we jump into the slides, you know, maybe, Steve, you can just tell people what the story is behind starting Atossa, 'cause I, you know, I always find it interesting how people start companies. Maybe we can start there, and then I'll jump into the slides. Yeah, happy to, Kyle. John again, thank you so much for hosting us today. I have this first slide up here, Atossa Therapeutics, and you see this profile of a woman. It turns out to be Princess Atossa. The story of the founding is pretty simple. About a decade ago, I was at the UCLA Library doing some research around the discovery of the Pap smear for cervical cancer. George Papanicolaou, a pathologist from New York City, had developed a way of looking at scrapings of the cervix under the microscope and not being able to see cancer, but be able to see the 10-year process that cervical cancer went through before it actually became cancer. I remember the day as like it was yesterday. I said, "Why isn't there a similar test for breast cancer?" Atossa was launched with that as our aspirational goal, to basically identify the precursors to breast cancer and to intervene in that ten-year period of time. This has led me to invent Endoxifen, which we are currently using in mammographic breast density studies in Sweden. We're now at the FDA looking at additional indications for Endoxifen. You know, every great story has a first step or every journey has a first step, and that was how Atossa got started. Thanks. Thanks, Steve. Why don't I jump into the slides here? Atossa, of course, is a Nasdaq publicly traded company. Please refer to our SEC filings before making an investment. Atossa Therapeutics is a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, and we're currently focused on breast cancer and COVID-19. Corporate summary. You know, we're headquartered in Seattle, Washington. As of the end of June, we have no debt. We have $126 million in cash, which is multiple years of runway based on our historic burn. And I also produced a you know snapshot of the cap table here to simplify things for folks. Essentially, we have common shares outstanding, and some warrants that are out of the money and some convertible preferred, so pretty straightforward cap table for a biotech company. Our management consists of Dr. Quay and myself, also Dr. Heather Fraser, Delly Behen and Heather Reese, each of the members of management have, you know, decades of experience in biotech. Let me jump in by talking about the pipeline here a little bit. You know, on endoxifen, our lead program, we have a phase 2 study underway in Stockholm, Sweden, where we are using our endoxifen to attempt to reduce mammographic breast density. We are also in the process of starting a phase 2 study here in the United States, in what's called the neoadjuvant setting, which is for women who have breast cancer, but is before they go in for their surgery. Now, this will be the first study in endoxifen that we've conducted in the United States, so this will be a major event for Atossa to bring a phase two study here in the U.S. with endoxifen. We have also recently completed a phase two study down in Australia in this neoadjuvant setting, and the success from that study is really the impetus for us continuing the development here now in the United States. We also have our inhalation therapy drug, which we also call AT-H201. We recently completed a phase one study with this inhalation therapy, and we have recently announced that we're gonna shift the focus of this therapy to address compromised lung function, which many cancer patients suffer from, particularly from radiation therapy. Dr. Quay will talk more about that in a minute. Finally, we have our COVID-19 nasal spray program, which we also call AT-301. I wanna talk about the market opportunities here because our philosophy has been that if we're gonna work on something, we'll work on something with a big market opportunity. Oral endoxifen in this neoadjuvant setting, again, which will be, you know, the next step for that will be a study here in the United States. That's for ER positive, HER2 negative breast cancers. Each of those categories, you know, consist of about 80% of all breast cancers, so that's a patient population of about 200,000 here in the United States. The mammographic breast density, you know, that indication is also very large. There are about 25 million women in the United States that have breast density, and that gets reported to them now through mammography. A woman goes in every year, every two years, they have their mammogram, and it is now law in the United States that that woman be notified if she has dense breast tissue because it's a significant health concern. We also have our nasal spray for COVID-19 at-home treatment. That of course is an enormous potential patient population. You know, I checked this a day or two ago, and there are now almost 600 million reported cases of COVID-19. Obviously, there are many more that have gone unreported. Finally, our inhalation therapy for lung injury caused by cancer treatments. This is surprisingly prevalent. About 30%-40% of lung cancer patients suffer from lung injury caused by the therapy. Those are the markets. At this point, why don't I turn it over to Dr. Quay and so you go ahead and I'll drive the slides from here. Okay. Great. Thanks, Kyle, for those who are following maybe on the website, we're on slide nine. Breast cancer is obviously a major problem. It's one out of eight women will experience breast cancer in their life. Again, about 281,000 diagnosed in the U.S., and as Kyle indicated, the most common of the four or five different types is ER positive, which is about 200,000 in the U.S., much closer to 1 million worldwide. It's the second leading cause of cancer death in American women. Next slide, please. If you think about the care path for breast health, which begins with prevention, goes through the neoadjuvant or window of opportunity, this is when at the time of diagnosis, treatments are sometimes used, and finally the adjuvant setting when radiation and surgery has been done, and now we're in the m-mode of trying to prevent local recurrence and metastatic disease. In the area of prevention, just like the Pap smear identifies not cervical cancers, but the pre-cancerous changes, mammographic breast density does the same thing in the breast. Doing a study in Sweden to see can we reduce density? 'Cause we know in women where density is reduced by in other ways, their risk of breast cancer also goes down, and then looking at the durability of that change. Once it does go down, can the women come off drug and maybe you've basically reset their lifetime risk. Now, the second group was women who are newly diagnosed. There's this period of time, it's sometimes called a window of opportunity, between the diagnosis, so they've had a mammogram or a physical exam, there's a lesion, there's a needle biopsy, it's been put on the microscope, and we know it's ER positive. Surgery, radiation is then 2-4 weeks, five weeks maybe into the future, and during that period of time, we wanna treat those cancers to stop the growth of the cancer even before we get to the definitive surgery. So this neoadjuvant window of opportunity is something that surprisingly is not available for most ER positive breast cancers. Definitely available for HER2 positive, definitely available for triple negative, because they're more aggressive. Only Endoxifen has the rapid PK, the rapid dynamic that allows it to get in the bloodstream fast enough to do something within that 2-6-week period of time. And finally, again, after definitive surgery and radiation, you wanna keep the woman in a state where she doesn't have a local recurrence and she doesn't have distant mets, and that's called the adjuvant setting, and that typically is 3-5 years of therapy. Next slide, please. Next slide. Our phase two study that we did in Australia was a precursor for what we filed with the U.S. It basically took women during the screening period of time and then treated them with endoxifen for the period between their diagnosis and their definitive surgery. We were able to take a biopsy, of course, at the time of diagnosis. We had surgical specimens, and we could compare the tumor response. Was the tumor not reproducing in the presence of endoxifen? Next slide, please. The measure of whether a cancer is dividing is called Ki-67. Basically is a percentage where the numerator is the number of cells that are dividing, one cell becoming two, the denominator is all cells. You want to see a reduction of that as much as you can. In a very quick time in our first seven patients, six out of the seven had a 65% reduction in Ki-67, and it actually went below 25%, which meant only less than one in four cells was dividing. That's been shown in the past to be very predictive of what happens two to three years into the future. We met both a strong statistical signature of reduction and a strong clinically significant signal of reduction in all patients getting below 25%. This trial was designed by our statistician to have gone much longer because he expected we might not get an efficacy effect. We got such a strong effect, he said, "Look, we've proven that endoxifen works in this setting. Let's pivot to a definitive trial in the U.S.. That's where we are right now. Next slide. Our goal is obviously to conduct this additional study in the U.S.. We filed a protocol in the U.S. with the FDA, got some feedback from them. We are responding to that feedback now in real-time, and we'll be updating you know, in the next few months, on what our progress is. When we do that, we'll lay out who the lead investigator is, who the sites are, and those sorts of things. Next slide. We've talked about mammographic breast density, but what is it? As shown here, there's a slide, a picture of a mammogram on the left with a cancer shown as a small, discrete white spot. The mammogram on the right is a woman who may or may not have breast cancer, but definitely has what's called mammographic breast density. Translation, her breast is mostly white. Some radiologist said, you know, "Finding cancer in that breast is like finding a polar bear in a snowstorm," because it's a white cancer dot that you're looking for on the top of a white background. What we wanna do is reduce that. Next slide shows the trial design. It's being done at the Karolinska Institutet in Stockholm, Sweden, by Dr. Per Hall, who has one of the largest collections of women over 70,000 women, who have undergone various specimens collections and histories, you know, companies like Atossa and many other companies, frankly, around the world, leading biopharmaceutical companies go to him to do clinical trials. He's a very sought-after investigator. He's very excited about this trial, among all the things he does. Next slide. Now pivoting to the inhalation therapy, what we call AT-H201. We have now completed the phase one trial to show that this is safe under the conditions that we'd like to use in the clinical setting. In doing the phase one trial in Australia and in listening to clinicians, frankly, the clinicians came to us and said, "Look it, this looks extremely safe, and it looks like it could be very valuable in an indication for which we really don't have much clinical opportunity." That is the iatrogenic or physician-induced lung damage that occurs in radiation when radiation is given to the chest for lung cancer, mediastinal cancers, esophageal cancers, and the like. The oncologists, they get a little bit of tunnel vision. Their focus is, "Can I kill this cancer? When the cancer is dead, I hand the patient off to the other physicians." In that handoff, the internal medicine doctor whoever that patient goes to is now stuck with a patient who may have significant reductions in pulmonary function because of the very therapy that probably saved their life. The question is: Can we both save their life with the radiation but prevent the damage to the lung by an intervening nebulized formulation? The clinicians think this meets the criteria of being something that's very much worth testing. Next slide. Dr. Paul Wabnitz is the physician who came to us and really championed that we should do this. You know, I'm reminded of a doctor at UCLA who came to Genentech's board of directors when they were going to kill a particular antibody drug for breast cancer, and pounded the table and basically said, "Look it, you need to develop this for HER2 positive breast cancer." Of course, the most successful breast cancer antibody in history came about from that interaction. Paul came to us in much the same light, and he said, "Look it. I've just been your monitor for your phase one study with this drug. I really like the safety profile, but I've also done some research. I think this has important legs in another indication." We are now putting together a protocol to actually address that, where we'll take patients who are going to have radiation for some cancer in their chest cavity, and immediately afterwards, we'll pivot to a placebo-controlled trial of intervention with our nebulized formulation, with the endpoint being, can we reduce the damage to the lungs? Paul is, you know, an esteemed executive, MD, PhD, also from the Ann Arbor area where I went to University of Michigan. He was at Parke-Davis/ Pfizer there for a long time, and is now back in his in Australia. The next slide, I think, is a very telling slide 'cause this is what an oncologist calls a major success. In the left panel, you have a chest X-ray, CT scan of a patient with a discrete white circle in the right lobe, which is a lung cancer. This is before radiation. The picture on the slide on the right is 1 year later, same image, same section through the chest, CT. What you see now is a lot of white scarring. It almost looks like the tumor is still there because it actually got bigger. You also see the lung, the black part of the lung, pulling away from the wall of the chest, the bony part of the ribcage. The oncologist says, "This is as good as it gets because this patient probably would have died, and I've saved his life." His internist is saying, "Well, you know, yes, but he now has only about a 30% lung capacity of a normal person, which he didn't have before that radiation." Next slide is even more telling. Lot of lines and colors, but I'll focus on just the A panel on the left, on the top, where you have percents from 100 to zero on the Y-axis, and you have months on the X-axis, 0-72, about six years. If you look at the yellow one in the middle, you actually see patients having about a 50% 5-year, 6-year survival for their These are patients with lung cancer that are treated. Did they die of their lung cancer, though? That's the question I wanna focus on here. No. They died of the ancillary damage to their lung that occurred because of the radiation therapy. This is an oncology success, but a collateral damage failure. This is a really big population because, you know, even I wasn't aware that one out of two people who die of lung cancer six years out didn't die of the cancer. They died of the reduced lung capacity, pneumonia, other side effects from the treatment itself. This is what we want to address. Next slide. What you're gonna hear over the next few months from Atossa is we're gonna define the target patient population. We're developing clinical study protocols. This is an ongoing process. We meet several times a week in various groups to fine-tune this. We need to refine the API and make supplies for the study, and identify any additional preclinical studies. We don't think there are at this point in time. Identify a location for the next clinical studies, and then file regulatory filings. This will be a lot of activity for Atossa now and into the fall and into next year. Next slide. Yeah. Do you want me to take it over from here, Steve, and ramp up the slides, and then we can go into Q&A? Why don't we do that? Sounds good. All right. I'll skip our board of directors just in the interest of time here. Milestones coming up. I'll start here at the bottom of the slide. I'm on slide 23 for people following along. The study that we're conducting in Stockholm to reduce breast density is underway, and people are asking how far along is that study. We hear you, and we will provide news on that before the end of the quarter here, which is, you know, five weeks away. What we plan on doing is provide an update on how many patients have enrolled in that study. It's a total of 240 patients. By telling folks how many have enrolled, you can kind of see the trajectory that the study is under aiming towards ultimate completion. Our other milestones coming up here, like Dr. Quay was just explaining, we've shifted the focus of our inhalation therapy now to compromised lung function caused by cancer treatment, so there'll be news on that coming up. Finally on the neoadjuvant study in the United States, you know, we filed an IND with the FDA to start that study here in the United States. We got feedback from them. They requested more information, so we're in the process of gathering that information, and we plan on filing that information with the FDA by the end of this quarter, the third quarter, and then we hope to get approval to open the study in the fourth quarter. We should have some very significant developments on that program coming up between now and the end of the year. John, you know, that's it for the formal presentation. I think we have a few minutes left for Q&A, and I know we've received a number of questions. Do you wanna tee those up for us, John? Thank you. Yes. Thank you, gentlemen, for presenting the latest on Atossa. Yes, we do have a number of questions that the tribe has sent in, which is part of this process to give you this direct corporate access to the companies you care about. In this case, it's Atossa. Let me start with the first question here in no certain order. By the way, tribe, if we don't get all questions answered today or something else pops up, we'll look to get Atossa back on. Continue to express your interest through the wish list process at the Tribe Public website. First question is with regard to the inhalation delivery. Is there a competing drug on the market now? If so, what is AT-H201 delivering that is unique? That's a great question. I mean, it is a proprietary formulation of two drugs that are previously FDA approved, but only one is for inhalation, and the other is approved for subcutaneous injection. Its mechanism of action is unique in the effect that it has on pulmonary epithelium, which is where it has its action. There is no currently approved drug or drug investigation that I'm aware of for the pulmonary damage from oncology radiation to the chest. We're really excited about this opportunity. It's a significant unmet medical need. As I've indicated, oncologists don't see this as a problem, but certainly, the internists that take care of patients afterwards do. It's hundreds and hundreds of thousands of patients. Got it. Thank you, Steve. It's a follow-up and similar, and you've sort of answered this already, but we're gonna go with it. It says, help us understand the shift towards compromised lung function patients. Can you give us a little more color there? Yeah, sure. Well, I mean, Princess Atossa is the first woman with breast cancer in recorded history, so we started as, you know, a pure oncology company preventing and treating breast cancer. We've expanded into oncology in general. I think that this fits exactly in that because, you know, you can't treat a lung cancer patient without causing the damage from that, and being able to provide a solution to that would be really gratifying. Thank you, Steve. Next question says, how far along is Atossa with the MBD enrolling? How many people do you have signed up so far? What can you tell us? Yeah. You know, on that, I can take that one, John. Again, we'll provide an update by the end of this quarter, which, you know, is only five weeks away from now. An update on how many patients have enrolled. We're just not ready to provide an update yet. Got it. Okay. Thank you. Thank you, Kyle. The next question says, as for the AT-H201, now that you're redirecting the drugs towards oncology, do you have to go back to phase one since it'll be used for something other than COVID? Another great question, but just a reminder, you know, after having developed seven drugs, I probably could do a master class on the topic. Phase one is always in normal volunteers, and it's always primarily looking at the safety of the drug. You can sometimes get signals of efficacy, but these are by definition, people who do not have a disease. Phase one will cover in almost 90+% of the cases all of your future indications. In phase two is the first time you're getting into patients with the condition that you hope to get approval for. Phase two is to define all the parameters around that final trial design, so that you don't get surprised in your phase three trial. Got it. Thanks, Steve. Makes sense. With regard to oral endoxifen, the phase two FDA submission, how close is the company to meeting the delivery of the additional data requested by the FDA? Yeah. Again, we're in the process of gathering that data and supplying it to the FDA. Our published timeline is that we'll provide that by the end of the quarter. I suspect when we send it in, the FDA would put out a press release to let people know where we're at. Our hope and expectation is that the FDA accepts what we will be sending them and that we'll then be able to open our study before the end of the year. Okay. Thank you, Kyle. The next question is, why did you put the SAB back in place, and can you speak a little bit more about Paul Wabnitz and how he's made the value he's going to drive by joining this team? Well, sure. Look at, I mean, everybody, including Atossa, had a before COVID and a during COVID and now hopefully an after COVID phase. We really wanted to emphasize being able to really get back together again in person or through Zoom processes. Reestablishing the SAB would seem like a very good thing to do at this point in time. Adding Paul is just he is such an advocate for this process and is a deeply you know steeped clinician in oncology, probably 15, 20 years of being an oncology doc, taking care of cancer patients, watching him being successful, getting rid of the cancer and being unsuccessful, having the residual lung damage. When he saw an opportunity to fix that part of it, he is really excited about this. Okay. Thank you. Switching gears a little bit here. This is a question about the authorized shares. It says, when will there be another vote to increase authorized shares? Kyle. Yeah. I'll take that one. We, you know, we don't have a date for that. I'd say we're evaluating and monitoring the situation, getting feedback from our investors and the investment community in general. I suspect at some point in the future, we'll put it back on the ballot and see what our stockholders say. I mean, ultimately, it's up to our stockholders. You know, at this point, we're just, like I say, monitoring the situation. We don't have a specific date when this might happen. Okay. Switching gears again. Travis got us some interesting questions here. This one, it says, "Recently there was a major announcement that they intend to acquire a U.S.-based startup with licensing from a prominent U.S. adult and pediatric cancer treatment facility. Would you be able to shed more light on this acquisition or possible acquisition? Yeah. Thanks, John. That's a good question. You know, we don't have more details to provide right now. We're in the process of negotiating with this company to potentially acquire them or alternatively make a significant investment in them. The diligence process is well underway. You know, that process is confidential to be, you know, really just premature to say anything more about it. I can say, though, that we're very excited about immunotherapy in the CAR-T space in particular. I think that is an area of biotech that the investment community continues to be very excited about. Those companies are getting very nice valuations, you know, in general for the work that they're doing. We are constantly looking for ways to enhance our pipeline, to grow our product pipeline in a way that will create stockholder value. We think that this particular area, you know, CAR-T cell therapy, is pretty compelling. We do have, you know, significant cash on our balance sheet to finance a transaction. You know, more to come on that. You know, as folks know, we have till November 1 under our agreement with this company. We'll have news on or before then. Got it. Switching gears back to, I guess, back to the balance sheet. You sort of spoke to it. It says, "Since cash burn will be a concern in light of the acquisition, would you be able to provide any guidance?" Yeah. I, unfortunately, we can't, John. We just like most biotech companies, we do not provide guidance on cash flow projections. Okay. The next question is, "Any definitive timeline for a readout on the MBD trial?" Yeah. I guess I'll take that. You know, as a reminder, each woman enters the trial by having a mammogram and identifying her as being at high density to begin with. Then she goes into a placebo-controlled arm, where she gets drugged once a day for six months, gets repeat mammograms in that period of time to show the decline. Then she goes off drug and will be monitored for another 18 months to look for durability. If the density did go down, does it stay down? All of that process is ongoing, and I think Kyle's indicated we're gonna make an update in the next few months on that program. Okay. Thanks. Yeah. I would just supplement that by saying that, you know, as Dr. Quay mentioned, the dosing period for this study is six months. This is not your typical large, expensive cancer study where patients are followed for five or 10 years to see if they have a recurrence. This is, you know, enrolling quickly. The dosing is relatively short-term. It's 6 months. And so we're excited about this completing and getting out data on it. Yeah. Kyle, just one more thing on this. You know, the vision we would have is that, look, a woman would not think about her breast health till she's 40, has her first mammogram, and then she's, you know, would typically spend the next, you know, 20-30 years doing mammograms every other year. In our picture of the future, the women who are at high density at 40, the doctor would say, "Well, you know, I got some good news and bad news. The bad news is you're at increased risk of breast cancer, but look, the good news is there's this drug you can take for six months, and in the clinical trials, if we're successful," you know, the doctor will be saying, you know, "It showed that it reduced the risk of breast cancer in this population. So you do it for six months. We'll check your mammogram. If it goes down, we know you're in the group of people who will perhaps have a future benefit." That's our vision of the future here. Again, that's two out of three out of four breast cancers worldwide are in that ER positive group. They all come from high density. I mean, not every high density woman gets breast cancer, but all breast cancers came from women who had high density at the time of their first mammogram. 10% of everything in biology violates whatever rule you make, but that's something you can kinda take to the bank. Well, you know, I personally, as you know, my mom had breast cancer and many other relatives I've known, and it's something that you know it means a lot to me. I'm you know I'm wishing you the best success here in this exploration, and looking forward to getting that to the market very soon. The next question it says, "Can you give us a status update on AT-301?" Yeah. Okay. I think we've said before, the FDA wants some additional studies on this, and we're diligently doing those studies. You know, when there's a data readout, and we can talk about it, we'll update you folks. Okay. I think you've sort of addressed this, but let's get it out there. It says, "For AT-H201, is there any further pipeline update that you might provide at this time?" I think we- Yeah. No. I mean, the pipeline is that we're going to develop it for, you know, compromised lung function caused by cancer treatment. Yeah, we don't have further details now. We're, you know, conversely not continuing the development in COVID patients. Okay. Switching back to endoxifen and the phase two trial. Can you give us any idea of how many locations, where these are, for the trial, et cetera? Yeah. I mean, I appreciate the anxiousness to have these details. We think the best way to do this is to put them all out at the same time where we're announcing on the back of FDA clearance to begin the trial, on the back of institutional review board approvals to begin the trial, and then we'll lay that out. You know, I think one thing we'll be adding at that point in time is an important point, we'll be using our patented endoxifen for the trials. Which is something which was recently achieved by the company. It's always an important milestone to get patents around everything you've done. I have 88 patents, so this was. Well, I had 87 before this is my 88th patent. It's an important achievement for Atossa's shareholders and stakeholders. Good. Thank you. Thank you, Steve. In respect of time and our sort of approximate 30-minute sort of window, we've exceeded that a bit, so I'm gonna. We've exhausted some questions that the Tribe had sent. I wanna, you know, I guess, put it back to you for any closing statements, and then I'll thank the Tribe after that. Is there anything else you'd like to add? You know, I would just say again that, you know, the vision I had in the UCLA library a decade ago that a company could be developed that could make a major impact on most important cancer, breast cancer. Because of your willingness to finance Atossa, we've been able to expand looking at immunotherapies or, you know, looking at other ancillary diseases like pulmonary damage in radiation. We really appreciate the investors who are along on this journey with us. I look forward to the day when we can change the paradigm of some of these cancers in a major way. Well, again, thank you, Steve and Kyle for joining us today. Of course, all of the Tribe members that joined us from around the world, appreciate your participation, your questions, and your expression of interest through the wish list process. Please keep that coming. If we didn't, again, get everything answered today, you know, please again express your interest in having Atossa back on through the wish list at the Tribe Public website, on a go-forward basis. It sounds like we have an exciting fall, and end of the year run here with Atossa, and I'm looking forward to your success. Again, remember, the symbol is Nasdaq ATOS. Gentlemen, I appreciate the time and everybody today, and I will bid you a good rest of the week, and look forward to hearing more about your success in the future. Thank you so much and, we'll talk to you soon. Thank you John. Thank you. Bye.